# ACE2-independent entry factors for SARS-CoV-2 infection and immune activation

**Authors:** Yiyu Sun, Lok-Yin Roy Wong, Theresa L. Chang

PMC · DOI: 10.1128/mbio.01897-24 · 2025-12-22

## TL;DR

This review explores how SARS-CoV-2 can infect cells without using the ACE2 receptor, highlighting alternative pathways and their impact on immune responses.

## Contribution

The paper identifies and reviews multiple ACE2-independent factors involved in SARS-CoV-2 infection and immune activation.

## Key findings

- SARS-CoV-2 can infect cells lacking detectable ACE2 expression.
- ACE2-independent entry factors may confer resistance to some monoclonal antibodies targeting the spike RBD.
- These factors can elicit immune responses independently of ACE2-mediated entry.

## Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), remains a major public health threat, particularly in vulnerable populations. SARS-CoV-2 spike proteins interact with the human angiotensin-converting enzyme 2 (ACE2) receptor, together with accessory molecules that facilitate viral entry, through its spike receptor-binding domain (RBD). Although ACE2 is the primary receptor required for viral replication, its expression patterns do not fully correlate with viral distribution or tissue pathology. Moreover, SARS-CoV-2 has been shown to infect cells and tissues lacking detectable ACE2 expression. Viral entry via ACE2-independent pathways may also confer resistance to some monoclonal antibodies (Abs) targeting the spike RBD that block ACE2-mediated binding. These observations highlight the potential significance of ACE2-independent entry factors in SARS-CoV-2 infection, particularly in vaccinated individuals with Abs directed against ACE2-dependent viral entry. In this review, we discuss the emerging roles of ACE2-independent entry factors in SARS-CoV-2 infection and the immune responses. These factors include CD147, AXL, CD169/Siglec-1, CD209L, CD209, CLEC4G, ASGR1, LDLRAD3, TMEM30A, TMEM106B, transferrin receptor 1, GPR78, integrin α5β1, KREMEN1, LFA-1, and CD4. While ACE2 remains central to viral replication, ACE2-independent entry appears sufficient to elicit immune responses. Therefore, future investigations are warranted to elucidate the roles of ACE2-independent mechanisms in immune-mediated pathology and viral evolution, independent of immune pressure targeting ACE2-mediated entry in previously infected or vaccinated individuals.

## Linked entities

- **Genes:** ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272], BSG (basigin (Ok blood group)) [NCBI Gene 682], AXL (AXL receptor tyrosine kinase) [NCBI Gene 558], CLEC4M (C-type lectin domain family 4 member M) [NCBI Gene 10332], CD209 (CD209 molecule) [NCBI Gene 30835], CLEC4G (C-type lectin domain family 4 member G) [NCBI Gene 339390], ASGR1 (asialoglycoprotein receptor 1) [NCBI Gene 432], LDLRAD3 (low density lipoprotein receptor class A domain containing 3) [NCBI Gene 143458], CDC50A (cell division cycle 50 P4-ATPase accessory subunit A) [NCBI Gene 55754], TMEM106B (transmembrane protein 106B) [NCBI Gene 54664], GPR78 (G protein-coupled receptor 78) [NCBI Gene 27201], KREMEN1 (kringle containing transmembrane protein 1) [NCBI Gene 83999], ITGAL (integrin subunit alpha L) [NCBI Gene 3683], CD4 (CD4 molecule) [NCBI Gene 920]
- **Diseases:** coronavirus disease 2019 (MONDO:0100096), COVID-19 (MONDO:0100096)

## Full-text entities

- **Genes:** TMEM106B (transmembrane protein 106B) [NCBI Gene 54664] {aka HLD16}, LDLRAD3 (low density lipoprotein receptor class A domain containing 3) [NCBI Gene 143458] {aka LRAD3}, ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}, GPR78 (G protein-coupled receptor 78) [NCBI Gene 27201], S (surface glycoprotein) [NCBI Gene 43740568] {aka spike glycoprotein}, ITGAL (integrin subunit alpha L) [NCBI Gene 3683] {aka CD11A, EV6, HNA-5, LFA-1, LFA1A}, KREMEN1 (kringle containing transmembrane protein 1) [NCBI Gene 83999] {aka ECTD13, KREMEN, KRM1}, SIGLEC1 (sialic acid binding Ig like lectin 1) [NCBI Gene 6614] {aka CD169, SIGLEC-1, SN}, BSG (basigin (Ok blood group)) [NCBI Gene 682] {aka 5F7, CD147, EMMPRIN, EMPRIN, HAb18G, OK}, CLEC4M (C-type lectin domain family 4 member M) [NCBI Gene 10332] {aka CD209L, CD209L1, CD299, DC-SIGN2, DC-SIGNR, DCSIGNR}, ASGR1 (asialoglycoprotein receptor 1) [NCBI Gene 432] {aka ASGPR, ASGPR1, CLEC4H1, HL-1}, CLEC4G (C-type lectin domain family 4 member G) [NCBI Gene 339390] {aka DTTR431, LP2698, LSECtin, UNQ431}, AXL (AXL receptor tyrosine kinase) [NCBI Gene 558] {aka ARK, AXL3, JTK11, Tyro7, UFO}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CD209 (CD209 molecule) [NCBI Gene 30835] {aka CDSIGN, CLEC4L, DC-SIGN, DC-SIGN1, hDC-SIGN}, CDC50A (cell division cycle 50 P4-ATPase accessory subunit A) [NCBI Gene 55754] {aka C6orf67, TMEM30A}
- **Diseases:** COVID-19 (MESH:D000086382)
- **Species:** Homo sapiens (human, species) [taxon 9606], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12892997/full.md

---
Source: https://tomesphere.com/paper/PMC12892997